Insidensi dan Karakteristik Hepatotoksisitas Obat Antituberkulosis pada Penderita Tuberkulosis dengan dan tanpa Infeksi HIV

Abstract

Hepatotoxicity is one of the complications in the treatment of tuberculosis (TB). Tuberculosis patient with HIV infection has higher risk in hepatotoxicity, and this is a clinical obstacle in dealing with TB-HIV treatment. The aims of this study were to find the incidence and characateristic of anti-tuberculosis hepatotoxicity in tuberculosis patients with and without HIV infection. A descriptive observational study was conducted in outpatient/inpatient RSUP Dr. Hasan Sadikin (RSHS) Bandung, and outpatient RS Bungsu period June–October 2012. There were 120 TB patients consisted of 18 patients with HIV and 102 patients without HIV. Most of TB patients with HIV occured in age ≤35 years (17/18 patients), male (12/18 patients), body mass index <18.5 kg/m2 (10/18 patients), and pulmonal TB (16/18 patients). TB patients with HIV had hepatotoxicity more than without HIV (9/18 vs 19/102 patients). The incidence of hepatotoxicity was 23.3%. Hepatotoxicity anti-tuberculosis drugs in TB patients with and without HIV infection mostly occured in second week therapy with mild degree. In conclusion, anti-tuberculosis hepatotoxicity is higher in TB patients co-infected with HIV than non-HIV infections.